Repaglinide Patent Expiration
Repaglinide is used for improving glycemic control in adults with type 2 diabetes mellitus. It was first introduced by Gemini Laboratories Llc
Repaglinide Patents
Given below is the list of patents protecting Repaglinide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Prandin | US6677358 | NIDDM regimen |
Jun 12, 2018
(Expired) | Gemini Labs Llc |
Repaglinide's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List